Читать книгу Assisted Reproduction Techniques - Группа авторов - Страница 203

1 1 Morice P. Borderline tumours of the ovary and fertility. Eur J Cancer. 2006; 42(2):149–58.

2 2 Morice P, Camatte S, Wicart‐Poque F, Atallah D, Rouzier R, Pautier P, et al. Results of conservative management of epithelial malignant and borderline ovarian tumours. Hum Reprod Update. 2003; 9(2):185–92.

3 3 du Bois A, Ewald‐Riegler N, de Gregorio N, et al. Borderline tumours of the ovary: a cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) Study Group. Eur J Cancer. 2013; 49:1905–14.

4 4 Palomba S, Zupi E, Russo T, Falbo A, Del NS, Manguso F, et al. Comparison of two fertility‐sparing approaches for bilateral borderline ovarian tumours: a randomized controlled study. Hum Reprod. 2007; 22(2):578–85.

5 5 Fauvet R, Poncelet C, Boccara J, Descamps P, Fondrinier E, Darai E. Fertility after conservative treatment for borderline ovarian tumors: a French multicenter study. Fertil Steril. 2005; 83(2):284–90.

6 6 Nam JH. Borderline ovarian tumors and fertility. Curr Opin Obstet Gynecol. 2010; 22(3):227–34.

7 7 Daraï E, Fauvet R, Uzan C, Gouy S, Duvillard P, Morice P. Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options. Hum Reprod Update. 2013; 19(2):151–66.

8 8 Tourgeman DE, Lu JJ, Boostanfar R, Amezcua C, Felix JC, Paulson RJ. Human chorionic gonadotropin suppresses ovarian epithelial neoplastic cell proliferation in vitro. Fertil Steril. 2002; 78(5):1096–9.

9 9 Basille C, Olivennes F, Le Calvez J, Beron‐Gaillard N, Meduri G, Lhommé C, et al. Impact of gonadotrophins and steroid hormones on tumour cells derived from borderline ovarian tumours. Hum Reprod. 2006; 21(12):3241–5.

10 10 Denschlag D, von Wolff M, Amant F, Kesic V, Reed N, Schneider A, et al. Clinical recommendation on fertility preservation in borderline ovarian neoplasm: ovarian stimulation and oocyte retrieval after conservative surgery. Gynecol Obstet Invest. 2010; 70:160–5.

11 11 Suh‐Burgmann E. Long‐term outcomes following conservative surgery for borderline tumor of the ovary: a large population‐based study. Gynecol Oncol. 2006; 103(3):841–7.

12 12 Uzan C, Kane A, Rey A, Gouy S, Duvillard P, Morice P. Outcomes after conservative treatment of advanced‐stage serous borderline tumors of the ovary. Ann Oncol. 2010; 21(1):55–60.

13 13 Boran N, Cil AP, Tulunay G, Ozturkoglu E, Koc S, Bulbul D, et al. Fertility and recurrence results of conservative surgery for borderline ovarian tumors. Gynecol Oncol. 2005; 97(3):845–51.

14 14 Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Mangioni C. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol. 2001; 19(10):2658–64.

15 15 Zanetta G, Rota S, Lissoni A. Ultrasound, physical examination and CA125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumours. Gynecol Oncol. 2001; 81:63–6.

16 16 Gallot D, Pouly JL, Janny L, Mage G, Canis M, Wattiez A, et al. Successful transfer of frozen‐thawed embryos obtained immediately before radical surgery for stage IIIa serous borderline ovarian tumour: case report. Hum Reprod. 2000; 15(11):2347–50.

17 17 Lawal A, B‐Lynch C. Borderline ovarian cancer, bilateral surgical castration, chemotherapy and a normal delivery after ovum donation and in vitro fertilisation‐embryo transfer. Br J Obstet Gynaecol. 1996; 103:931–2.

18 18 Bjørnholt S, Kjaer S, Nielsen T, Jensen A. Risk for borderline ovarian tumours after exposure to fertility drugs: results of a population‐based cohort study. Hum Reprod. 2015; 30(1):222–31.

19 19 Rizzuto I, Behrens R, Smith L. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Database Syst Rev. 2013;( 8), CD008215.